Peripheral Artery Disease

Peripheral Artery Disease (PAD) – High‑Yield Study Guide for Medical Students

Definition

Peripheral artery disease (PAD) is atherosclerotic occlusive disease of the arteries supplying the limbs, most commonly the lower extremities, leading to impaired blood flow and ischemic symptoms. It is a manifestation of systemic atherosclerotic cardiovascular disease and is strongly associated with coronary artery disease (CAD) and cerebrovascular disease.

Epidemiology

PAD is common, particularly in older adults, and is frequently underdiagnosed because many patients are asymptomatic or have atypical leg symptoms.

• Prevalence increases with age; affects ~10–20% of people >60 years, higher in those >70 years.
• Strong association with tobacco use, diabetes mellitus, hypertension, dyslipidemia, and chronic kidney disease.
• More common in men historically, but sex differences narrow with age; women may be more often asymptomatic.
• PAD is an independent predictor of myocardial infarction, stroke, and cardiovascular mortality.

Pathophysiology

The dominant mechanism in PAD is atherosclerosis of medium and large arteries supplying the lower (and sometimes upper) extremities.

• Endothelial injury and dysfunction: Caused by risk factors (smoking, hyperlipidemia, hypertension, hyperglycemia) leading to increased permeability, leukocyte adhesion, and impaired nitric oxide production.
• Lipid accumulation and inflammation: LDL infiltration into the intima, oxidation, and uptake by macrophages leads to foam cell formation and fatty streaks; chronic inflammation promotes plaque growth.
• Fibrous plaque formation: Smooth muscle cell migration and proliferation with extracellular matrix deposition results in fibrofatty plaques that narrow the arterial lumen.
• Stenosis and flow limitation: Progressive narrowing causes reduced perfusion pressure distal to the lesion, particularly during exercise when metabolic demand increases.
• Collateral circulation: Chronic obstruction can stimulate collateral vessel formation, which may partially compensate but is often insufficient in advanced disease.
• Critical limb ischemia: Severe stenosis or occlusion plus inadequate collaterals → rest pain, non-healing ulcers, and tissue loss due to chronic ischemia.

Less common causes of PAD-like presentations include thromboembolism (e.g., from atrial fibrillation), vasculitis, Buerger disease (thromboangiitis obliterans), popliteal entrapment, and cystic adventitial disease; however, in exam settings, atherosclerosis is by far the most important.

Clinical Presentation

PAD has a wide clinical spectrum from asymptomatic disease to limb-threatening ischemia and acute ischemia.

Typical Symptoms

• Intermittent claudication: Exertional pain, cramping, tightness, or fatigue in a muscle group distal to the lesion (most commonly calf) that is reproducible with a given level of exercise and relieved by rest within minutes.
• Atypical leg symptoms: Many patients have exertional leg pain not meeting classic claudication criteria, or nonspecific leg fatigue.
• Ischemic rest pain: Pain in the foot or toes, usually at night and relieved by dependency (dangling leg off the bed); suggests critical limb ischemia.
• Non-healing wounds or ulcers: Especially on toes, heels, or pressure points; may be painful or painless (especially in diabetics with neuropathy).
• Gangrene and tissue loss: Black, necrotic tissue or dry gangrene of digits or forefoot, representing advanced ischemia.

Physical Examination Findings

• Diminished or absent pulses: Femoral, popliteal, dorsalis pedis, and posterior tibial pulses may be weak or absent.
• Bruits: Femoral bruits suggest atherosclerotic disease at the iliac/femoral level.
• Skin and nail changes:
  • Cool, pale extremity; decreased hair growth on the shins.
  • Thin, shiny skin; brittle, ridged toenails.
  • Dependent rubor (redness when leg is down) and pallor on elevation.
• Capillary refill delay: Delayed return of color after compression.
• Muscle atrophy: From chronic underperfusion and disuse.
• Ankle-brachial index <0.9: Often assessed in clinic as part of the diagnostic workup (see below).

Levels of Disease and Symptom Patterns

• Aortoiliac disease: Claudication in buttocks, hips, thighs; diminished femoral pulses; may be associated with erectile dysfunction (Leriche syndrome: claudication, impotence, decreased femoral pulses).
• Femoral-popliteal disease: Most common; calf claudication, diminished popliteal and distal pulses.
• Infrapopliteal/tibial disease: Distal calf and foot symptoms, often associated with diabetes and critical limb ischemia.

Diagnosis

Diagnosis of PAD is based on a combination of clinical assessment and non-invasive vascular testing. Remember that PAD is a marker of systemic atherosclerosis, so evaluation for CAD and cerebrovascular disease is important.

Initial Assessment

• History: Risk factor assessment (smoking, diabetes, hypertension, dyslipidemia, family history), walking impairment, rest pain, non-healing wounds, and prior cardiovascular events.
• Physical exam: Vascular exam of all limb pulses, auscultation for bruits, inspection of skin and feet, neurologic exam (sensation, reflexes), and cardiac/neurologic exam.

Ankle-Brachial Index (ABI)

The ankle-brachial index is the primary non-invasive test to screen for and diagnose PAD.

• Method: Measure systolic blood pressure at the brachial artery and at the dorsalis pedis and posterior tibial arteries using a Doppler probe; ABI = highest ankle systolic pressure / highest brachial systolic pressure.
• Interpretation:
  • 1.00–1.40: Normal.
  • 0.91–0.99: Borderline.
  • <0.90: Abnormal, diagnostic of PAD in appropriate clinical context.
  • <0.40: Severe PAD, often associated with critical limb ischemia.
  • >1.40: Noncompressible arteries due to medial arterial calcification (common in diabetes and CKD), requiring alternative testing (e.g., toe-brachial index).

Additional Non-Invasive Testing

• Toe-brachial index (TBI): Used when ABI is >1.4 or arteries are noncompressible; toe arteries are less affected by calcification; TBI <0.7 suggests PAD.
• Exercise ABI testing: Useful when resting ABI is normal but symptoms are suggestive. ABI is measured before and after treadmill exercise; a drop >20% suggests PAD.
• Segmental limb pressures and pulse volume recordings: Help localize the level of disease.
• Doppler waveform analysis: Triphasic waveforms are normal; biphasic or monophasic waveforms suggest significant stenosis.

Imaging

Imaging is generally reserved for patients being considered for revascularization or when diagnosis is uncertain.

• Duplex ultrasound: First-line imaging modality; combines B-mode imaging with Doppler flow to detect stenosis and occlusions, and estimate severity.
• CT angiography (CTA): Provides detailed arterial anatomy from aorta to pedal arteries; useful for planning endovascular or surgical interventions; requires iodinated contrast and radiation exposure.
• MR angiography (MRA): Alternative to CTA, especially in patients with iodinated contrast allergy; gadolinium carries risk of nephrogenic systemic fibrosis in advanced CKD.
• Catheter-based digital subtraction angiography (DSA): Gold standard for anatomical detail and allows simultaneous endovascular intervention; invasive and typically reserved for patients in whom revascularization is planned.

Management

Management of PAD has three main goals: relief of symptoms, improvement in functional status and quality of life, and reduction of cardiovascular events and limb loss. Therapy includes lifestyle interventions, optimal medical management, structured exercise, and revascularization when indicated.

Risk Factor Modification and Medical Therapy

• Smoking cessation: Highest yield intervention; reduces progression, improves symptoms, and decreases CV events. Offer behavioral counseling, nicotine replacement, varenicline, or bupropion as appropriate.
• Antiplatelet therapy:
  • Aspirin (usually 75–100 mg daily) is recommended in symptomatic PAD for secondary prevention.
  • Clopidogrel 75 mg daily is an alternative, and some data suggest it may be slightly more effective than aspirin alone in reducing ischemic events in PAD.
  • Dual antiplatelet therapy is generally reserved for post-stent or certain high-risk scenarios.
• Lipid management:
  • High-intensity statin therapy (e.g., atorvastatin 40–80 mg, rosuvastatin 20–40 mg) is indicated for all PAD patients unless contraindicated.
  • Targets: major LDL reduction (≥50%) and LDL <70 mg/dL in most high-risk patients.
• Blood pressure control:
  • Goal consistent with current hypertension guidelines (often <130/80 mmHg) in most patients with PAD.
  • ACE inhibitors or ARBs are preferred due to additional cardiovascular protective effects.
• Glycemic control in diabetes:
  • Optimize glycemic control to reduce microvascular and macrovascular complications; individualize HbA1c targets (often ≤7%) considering comorbidity and life expectancy.
  • Ensure foot care and early treatment of infections.
• Antithrombotic strategies beyond aspirin:
  • In selected high-risk PAD patients, low-dose rivaroxaban (2.5 mg BID) plus aspirin has been shown to reduce major adverse cardiovascular and limb events, at the expense of higher bleeding risk. Use is tailored to individual risk-benefit profiles.

Exercise Therapy

• Supervised exercise therapy (SET):
  • Core component of PAD management and often first-line for lifestyle-limiting claudication.
  • Typically: treadmill or track walking, 3 times per week, 30–45 minutes per session for at least 12 weeks.
  • Patients walk until moderate-to-maximum claudication pain, then rest, repeating cycles during each session.
  • Improves walking distance, functional capacity, and quality of life; may be as effective as revascularization for claudication in some patients.
• Home-based exercise programs: A structured, walking-based program with behavioral support is better than no exercise, but typically less effective than supervised programs.

Pharmacologic Treatment for Claudication Symptoms

• Cilostazol:
  • Phosphodiesterase III inhibitor with vasodilatory and antiplatelet properties.
  • Dose: typically 100 mg orally twice daily.
  • Improves maximal and pain-free walking distance in patients with intermittent claudication.
  • Contraindicated in heart failure due to increased mortality seen with similar agents.
• Naftidrofuryl, pentoxifylline, and others: Used in some regions but generally less effective; pentoxifylline is largely considered obsolete for PAD in many guidelines.

Revascularization

Revascularization is considered for patients with lifestyle-limiting claudication refractory to optimal medical therapy and exercise, and for all patients with chronic limb-threatening ischemia (rest pain, non-healing ulcers, gangrene).

Endovascular Therapy

• Techniques:
  • Balloon angioplasty (percutaneous transluminal angioplasty, PTA).
  • Stent placement (bare-metal or drug-eluting).
  • Atherectomy (plaque debulking), and drug-coated balloons in selected cases.
• Advantages: Minimally invasive, shorter recovery, suitable for focal lesions and high-surgical-risk patients.
• Best suited for: Short segment aortoiliac and femoropopliteal lesions; some tibial lesions depending on anatomy and expertise.

Surgical Revascularization

• Bypass surgery:
  • Use of autogenous vein (preferred) or prosthetic grafts to bypass diseased segments.
  • Examples: femoropopliteal bypass, femorotibial bypass, aortobifemoral bypass.
• Endarterectomy: Removal of plaque from the artery (e.g., common femoral endarterectomy).
• Amputation: Reserved for non-salvageable limbs in advanced gangrene, uncontrolled infection, or intractable pain when revascularization is not feasible.
• Choice of procedure: Depends on anatomical pattern (TASC classification), patient comorbidities, life expectancy, and local expertise; often guided by a multidisciplinary vascular team.

Management of Chronic Limb-Threatening Ischemia (CLTI)

• Definition: PAD with ischemic rest pain, non-healing ischemic ulcer >2 weeks, or gangrene attributable to arterial occlusive disease.
• Principles:
  • Urgent evaluation for revascularization (endovascular, surgical, or hybrid approaches).
  • Aggressive risk factor control and antithrombotic therapy.
  • Meticulous wound care, infection control, and offloading of pressure.
  • Coordination with podiatry, wound care, and sometimes infectious disease.

Key Clinical Pearls (Exam-Focused)

• PAD is a systemic atherosclerotic disease: Always think beyond the limb; PAD patients have a high risk of MI and stroke. Managing cardiovascular risk is as important as treating claudication.
• Classic claudication triad: Reproducible exertional pain in a muscle group, relief with rest, and recurrence with a similar degree of exertion; calf claudication usually indicates femoropopliteal disease.
• ABI thresholds: <0.9 diagnostic of PAD; <0.4 indicates severe disease; >1.4 suggests noncompressible vessels (consider TBI).
• Leriche syndrome: Aortoiliac occlusion presenting with buttock/thigh claudication, impotence, and decreased femoral pulses.
• Differentiate PAD from neurogenic claudication: Neurogenic claudication (lumbar spinal stenosis) is relieved by flexion or sitting, not just stopping; pain may ascend proximally and is less predictable with exertion.
• First-line therapy for claudication: Risk factor modification, antiplatelet therapy, statins, and supervised exercise; revascularization is considered when symptoms remain disabling.
• Cilostazol improves walking distance in claudication but is contraindicated in heart failure.
• Critical limb ischemia requires prompt revascularization assessment: Features include rest pain, non-healing ulcers, or gangrene; delay increases risk of major amputation.
• Always examine pulses and feet in diabetics and smokers: PAD is frequently silent until advanced; early detection can prevent limb loss.
• Use PAD as a red flag for aggressive prevention: Treat these patients like coronary artery disease equivalents in terms of risk reduction.

Summary for Exams

Peripheral artery disease is an atherosclerotic occlusive disorder of the limb arteries, most often affecting older patients with cardiovascular risk factors such as smoking, diabetes, hypertension, and hyperlipidemia. Intermittent claudication is the classic symptom, but many patients are asymptomatic or have atypical leg pain. PAD is diagnosed using the ankle-brachial index (ABI), with values <0.9 indicating disease. Management focuses on smoking cessation, statins, antiplatelet therapy, blood pressure and glucose control, and supervised exercise. Cilostazol can improve walking distance in appropriate patients, while endovascular or surgical revascularization is reserved for lifestyle-limiting claudication not responsive to conservative therapy and for chronic limb-threatening ischemia.